Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 25,700 shares at $44.95 ($1.2M) on 2017-09-13, disclosed to the SEC on 2017-09-14.
Open-market sale of $1.2M JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.95 | 12,850 | $578K | 50.0% |
| 2 | $44.95 | 12,850 | $578K | 50.0% |
| Total | $44.95 avg | 25,700 | $1.2M | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |